

Investor Relations

Like { 5

Tweet { 0

Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Bausch + Lomb on August 5, 2013. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division, creating a global eye health platform with estimated pro forma 2013 net revenue of more than \$3.5 billion. For Investor Relations information on Valeant, [click here](#).



Vision and Eye Health

Vision and Age

Eye Infections & Irritations

Diseases and Disorders

Find a Doctor

Eye Exam Check List

Products

Contact Lenses

Contact Lens Care

Dry Eye Products

Allergy/Redness Relief

Rx Pharmaceutical

Eye Vitamins

Surgical Products

Vision Accessories

Customer Support

Contact Us

Customer policies and forms

Rebate Center

Worldwide Locations

Legal

Legal Notice

Privacy Policy

Safety Data Sheets (SDS)

Newsroom

Careers

Investor Relations

Grants & Contributions

© 2015 Bausch & Lomb Incorporated.

All information and materials on this site pertain to the U.S. only, unless otherwise indicated.